1. Home
  2. MNKD vs FOR Comparison

MNKD vs FOR Comparison

Compare MNKD & FOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNKD
  • FOR
  • Stock Information
  • Founded
  • MNKD 1991
  • FOR 2005
  • Country
  • MNKD United States
  • FOR United States
  • Employees
  • MNKD N/A
  • FOR N/A
  • Industry
  • MNKD Biotechnology: Pharmaceutical Preparations
  • FOR Real Estate
  • Sector
  • MNKD Health Care
  • FOR Finance
  • Exchange
  • MNKD Nasdaq
  • FOR Nasdaq
  • Market Cap
  • MNKD 1.1B
  • FOR 1.0B
  • IPO Year
  • MNKD 2004
  • FOR 2007
  • Fundamental
  • Price
  • MNKD $4.06
  • FOR $25.12
  • Analyst Decision
  • MNKD Buy
  • FOR Strong Buy
  • Analyst Count
  • MNKD 6
  • FOR 4
  • Target Price
  • MNKD $9.33
  • FOR $30.25
  • AVG Volume (30 Days)
  • MNKD 3.0M
  • FOR 203.7K
  • Earning Date
  • MNKD 08-06-2025
  • FOR 07-22-2025
  • Dividend Yield
  • MNKD N/A
  • FOR N/A
  • EPS Growth
  • MNKD 228.27
  • FOR N/A
  • EPS
  • MNKD 0.10
  • FOR 3.19
  • Revenue
  • MNKD $297,595,000.00
  • FOR $1,543,300,000.00
  • Revenue This Year
  • MNKD $13.72
  • FOR $3.95
  • Revenue Next Year
  • MNKD $14.94
  • FOR $8.86
  • P/E Ratio
  • MNKD $39.14
  • FOR $7.88
  • Revenue Growth
  • MNKD 32.50
  • FOR 2.35
  • 52 Week Low
  • MNKD $3.51
  • FOR $18.00
  • 52 Week High
  • MNKD $7.63
  • FOR $34.82
  • Technical
  • Relative Strength Index (RSI)
  • MNKD 55.84
  • FOR 71.61
  • Support Level
  • MNKD $3.74
  • FOR $21.65
  • Resistance Level
  • MNKD $4.13
  • FOR $26.04
  • Average True Range (ATR)
  • MNKD 0.14
  • FOR 0.89
  • MACD
  • MNKD 0.05
  • FOR 0.32
  • Stochastic Oscillator
  • MNKD 88.14
  • FOR 82.55

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

About FOR Forestar Group Inc

Forestar Group Inc is a residential lot development company with operations across the United States. The core business segment for the company is real estate which generates all of it's revenues. The firm fundamentally acquires entitled real estate and develops it into finished residential lots for sale to homebuilders with a strategic focus on asset turns and efficiency. Single-family residential communities account for the majority of their real estate projects. The company utilizes a lower-risk business model mainly by investing in short duration, phased development projects.

Share on Social Networks: